Oxford Genetics Opens First US Office

September 12, 2017
Pharmaceutical Technology Editors

The company has extended its presence in the US market to support its growing business in the region.

Synthetic biology company Oxford Genetics announced on Sept. 12, 2017 that it has opened its first office in the United States, located at the NGIN workplace near Kendall Square in the Cambridge district of Boston. Based in Oxford, United Kingdom and founded in 2011, the company is now expanding into the US market to support its growing business in the region. The investment reinforces the company’s commitment to delivering solutions that improve the discovery and development of biotherapeutics.

Oxford Genetics creates biology-based technologies to aid in the discovery and development of biologics, cell, and gene therapies. The company has experience in DNA design for the optimization of protein expression, improved viral delivery systems and cell line engineering.

Oxford Genetics is looking to grow its US commercial team within the next 18 months, build on collaborative partnerships, as well as strengthen its customer and technical support offering. This global expansion follows the company’s latest successful round of financing in which it secured a GBP 7.5 million investment that will also support the company’s 6000-square-feet expansion of its UK facility at Oxford Science Park. The expansion will include state-of-the-art cell line engineering capabilities, viral vector production and purification suites, high-throughput robotic screening systems, and process development facilities.

Source: Oxford Genetics